PhD in MATERIALS FOR SUSTAINABLE DEVELOPMENT

email: ghibelli@uniroma2.it
phone:

Curriculum vitae
LINA GHIBELLI
Associate Professor
Department of Biology University of Rome Tor Vergata

Born 01/08/1954 Venice (ITALY)

BIOGRAPHY
University Education:
June 1979: Degree summa cum laude in Biological Sciences, La Sapienza University (supervisor Prof. Enrico Calef).
Contracts and appointments:
• 1980-82 Research Associate, University of Chicago, Dept. of Biophysics (lab Prof. R. Haselkorn).
• 1982-83: Research Associate, University of Chicago, Dept. of Biology (lab Prof. S. Lindquist).
• 1986-88: Visitor at "European Molecular Biology Laboratory" Heidelberg, (lab Prof. R. Di Lauro)
• 1995: Visiting Scientist at Karolinska Institutet, Dept. of Toxicology (lab Prof. S. Orrenius)
• 1998-2002: Contract professor at the University of Urbino
• 2024: visiting scholar at University of Sevilla
Academic positions
• 1984-2015: Researcher Department of Biology, University of Rome Tor Vergata
• 2015-present Associate Professor, Department of Biology, University of Rome Tor Vergata
BIBLIOMETRY
> 300 publications; >120 papers in International peer reviewed journals
> 100 published abstracts; > 70 oral presentations at conferences/meetings.
H index:
50 (Google Scholar; 10793 citations; H10=90)
41 (Web of Science, 6918 citations),
44 (Scopus; 8074 citations);

MAIN SCIENTIFIC INTERESTS
Since 1991 Prof. Ghibelli leads a research group focused on the study of cell stress processes and damage-induced apoptosis (intrinsic or mitochondrial pathway), with emphasis on oxidative stress, cellular survival pathways, and how they can be modulated. Important modulators considered in the decades include magnetic fields, melatonin and more recently intrinsically active inorganic nanoparticles (nanozymes), with particular attention to cerium oxide nanoparticles (nanoceria). Currently, research is directed towards the biological aspects of the reprogramming of cancer cells that survive damage induced by chemotherapeutic agents, with a focus on the role of apoptosis and stress response in post-therapy repopulation, in particular on the surprising anticancer effect exerted by nanoceria. Very recently, she discovered an unexpected anti-inflammatory action of nanoceria, which has become a main focus of her translational research

Included among the "Top Italian Scientists"

1. SCIENTIFIC ACTIVITY:

1.1 Scientific path (numbers indicate the position of the cited articles in the list of total publications)
a) training period (1978-1990)
In the initial period, which took place in Italy, the USA and Germany, various research themes were explored, which involved various types of settings and technological approaches.
1978-1980, intern in Prof. Enrico Calef lab (La Sapienza University of Rome), research on the immortalization of murine pro-erythroblasts with Friend retrovirus.
1980-1982, in the laboratory of Prof. Robert Haselkorn (University of Chicago), research on the replication mechanisms of the dsRNA bacteriophage Phy6 (paper no. 1).
1982-1983, in the laboratory of Prof. Susan Lindquist (University of Chicago), research on the mechanisms of regulation of Drosophila heat shock mRNAs.
1984-1986, as Researcher in the laboratory of Prof. Calef (Tor Vergata), research on the mechanisms of immortalization of human lymphocytes with the Epstein-Barr virus.
1986-1988, in the laboratory of Prof. Roberto di Lauro (EMBL Heidelberg), research on the regulatory mechanisms of the thyroglobulin gene promoter (papers no. 2,3).
From 1989 to 1990, collaboration with Prof. Autuori's group (Tor Vergata Biology Department) on the role of the transglutaminase enzyme in the apoptosis process (works no. 4,5).
b) scientific contributions of the laboratory directed by Prof. Lina Ghibelli (1991-2023)
The period of scientific autonomy began in 1991; Prof. Ghibelli's laboratory has carried out independent research with autonomous problems; it is frequented by bachelor's, master's and doctoral students, and young post-doctorates, who have followed one another over the years in varying numbers and positions; has regularly made use of collaborations, at national and international level, especially when interdisciplinary issues have been addressed (e.g., with clinicians, materials scientists, physicists and chemists).
• Mechanisms of intrinsic apoptosis (1991-2015)
The laboratory was involved in this phase in the study of the molecular mechanisms that control the processes of cell death by apoptosis. The general approach has consisted of the exploration of innovative themes, consisting of pioneering studies which have, in various circumstances, paved the way for new lines of research which have been followed by many colleagues, as shown by the high levels of citations of the published works.
The lab focused on the mechanism through which stress/cellular damage induced by hyperthermic (6) or oxidative treatments (67) promote apoptosis, demonstrating the relationship between extent of damage and type of cell death (apoptosis or necrosis). The apoptosis process induced by factors released by stressed cells was also analysed, the molecular nature of which was partially characterized (8).
The role of ADP-ribosylation phenomena in triggering apoptosis was explored with a pioneering paper, demonstrating for the first time with a seminal work, that the activation of poly-ADP-ribosyl-Polymerase (PARP) plays a pro-apoptotic role (7) through signaling mechanisms (10,11). Furthermore, was demonstrated that mono-ADP-ribosylation reactions participate in cell survival programs playing an anti-apoptotic cell defense role (11,45). In particular, one of such reaction involves glyceraldehyde-3-phosphate dehydrogenase (23), a glycolytic enzyme subjected to post-translational regulation by ADP-ribosylation (18), thereby regulating damage-induced apoptosis (66).
For the first time, intermediate stages of the damage-induced apoptosis were characterised, through a morphological study at ultrastructural level, which allowed identifying three different modes of nuclear vesiculation (15), of which two occurring in interphase (budding and cleavage), and one in mitosis (later defined as mitotic catastrophe). These modes were later described at the biochemical level (12), thus outlining the dynamics of the apoptotic process.
A particularly fruitful line of pioneering research was the study of the role of glutathione, the main endogenous cellular antioxidant, in the apoptosis process; it has been shown that cells undergoing apoptosis actively extrude glutathione in its reduced form (13); a subsequent seminal work showed that glutathione extrusion occurs via specific transporters, and that the extrusion is necessary for the successive step of the apoptotic signalling (19). Moreover, it was shown that glutathione extrusion causes oxidative stress (27,28), which is the ultimate responsible for the activation of the intrinsic apoptotic pathway. These results were discussed in an invited review (24). Analysis of the molecular mechanisms of this activation led to two high-impact studies, showing that rapid extrusion of glutathione leads to dimerization and oxidative activation of the pro-apoptotic protein Bax (38), and to the subsequent release of cytochrome c from mitochondria (21). The role of glutathione extrusion in Bax activation was confirmed by observing the sensitization of human lung cancer cells to apoptosis in an oxidative environment (34). The role of such events in mitochondrial activation of Bax in apoptosis was discussed in (71).
The detailed analysis of the different independent apoptotic nuclear morphologies described in (15) allowed demonstrating that the oxidative imbalance affects only the intrinsic pathway, which produces an apoptotic morphology different from that produced by the extrinsic pathway (48) and implies a different role of the cytoskeleton (43).
• Cell survival pathways (2000-2015)
The study of the mechanisms of apoptosis induction was accompanied by the study of cellular defense mechanisms. These include the modulation of the anti-apoptotic protein Bcl-2 that, in situations of redox imbalance, such as rapid glutathione depletion, is transactivated in tumor cell lines (36) and in circulating monocytes (60) and lymphocytes (47); the trans-activation mechanism consists in the promotion of the non-canonical activation pathway of the redox-sensitive transcription factor NFkappaB (62). The role of glutathione depletion in apoptosis and survival pathways was analyzed in (83). The role of cellular organelles in the control of apoptosis and cell survival pathways was the subject of a special issue for which the relevant editorial was published (80).
Another cellular protection mechanism explored is exposure to magnetic fields; it was demonstrated for the first time, with a work still highly cited, that stress-induced apoptosis is hindered by static magnetic fields in hematopoietic cell types (20) and glial cells (25) via a mechanism of alteration of calcium fluxes, which was then identified as a non-capacitive influx of calcium across the plasma membrane (75). This provides a mechanistic basis for the proposed tumor-promoting role of magnetic fields (31). Searching for the molecular mechanisms of the anti-apoptotic effect of magnetic fields, it has been observed that magnetic fields alter the redox balance (44) and the polarity of the plasma membrane (42) and accelerate the process of secondary necrosis (26), i.e., the duration of membrane integrity of apoptotic cells. Surprisingly, strong magnetic field intensities exert the opposite effect of stimulating apoptosis: experiments performed within clinical magnetic resonance imaging (MRI) equipment, which reach values >1 Tesla, have in fact demonstrated that high intensity magnetic fields favor the pro-apoptotic activity of chemotherapeutic agents in tumor cells but not in normal cells, proposing magnetic resonance imaging as a possible adjuvant to anti-tumor therapies (49).
Another agent that counteracts apoptosis has proven to be the hormone melatonin, which reduces damage-induced apoptosis in monocytes (41), lymphocytes (70) and glial cells (68). The analysis of the mechanisms involved has allowed to demonstrate for the first time that the anti-apoptotic activity is due to the interaction of melatonin with the specific MT1 membrane receptors, activating a signal transduction pathway (54), which is responsible for translocation to the mitochondria of the anti-apoptotic protein Bcl-2, in a cellular district, therefore, where it is able to counteract the intrinsic apoptotic pathway (59). This occurs in spite of a surprising and robust pro-oxidant activity (63,46), limited to biological systems (N.B., chemically melatonin is an anti-oxidant), and deriving from the ability of melatonin to activate a cellular pathway that involves calmodulin, and culminates in the activation of the pro-oxidant and pro-inflammatory enzyme 5-lipoxygenase (64). The same pro-oxidant activity of melatonin is also able to activate a survival pathway mediated by NFkappaB, thus reinforcing the anti-apoptotic effect (69). Finally, it was demonstrated that melatonin anti-apoptotic effect requires the convergence at the mitochondrial level of the pathway triggered by high-affinity membrane receptors and the pro-inflammatory one triggered by low-affinity cytoplasmic receptors, leading to the sequestration of Bax by Bcl-2 in the mitochondrion, showing for the first time that mitochondrial translocation of Bax is not necessarily synonymous with activation (89). The effect of melatonin on apoptosis of myeloid and lymphoid cells in an inflammatory context was analyzed in a highly cited review (72).
In another set of study, the anti-apoptotic role of a mild hypoxic condition (preconditioning-like, 29) was also investigated. A further mechanism of cell survival has been identified in the process by which HIV protease inhibitors, a class of anti-AIDS drugs, inhibit apoptosis, contributing to the improvement of patients' status. In this regard, it has been demonstrated that viral protease inhibitors exert a cross-inhibition of the cellular protease calpain (32,50) involved in the mechanisms of apoptosis, thus providing a possible explanation for the surprising phenomenon of improvement in AIDS patients treated with the aforementioned drugs even in the absence of lowering of the viral titer.
Special attention was paid to the role of the Ca2+ ion in apoptosis, a problem that is still poorly clarified despite decades of studies; it has been demonstrated, through single cell analyses, that the apoptotic process alters Ca2+ homeostasis causing a different intracellular distribution (30, 53, 56, 57). Furthermore, a peculiar mechanism of detoxification from excess Ca2+ was identified during anoxia/reoxygenation experiments involving mitochondria: indeed, mitochondria uptake the excess of cytosolic Ca2+ induced by the inversion of the Ca/Na exchanger in reoxygenation, detoxifying the injured cells, after which they are extruded from the cell, which thus gets rid of excess Ca2+ (55). The role of calcium in apoptosis was analyzed in (74).
• Cellular anti-oxidant effects of bioactive cerium oxide nanoparticles (2004-present)
The lab in 2004 began to study the effect that nanotechnological agents, a promising new technological frontier in the field of biomedicine, exert on cellular systems in terms of cell stress and apoptosis (82, 84). Studies have been carried out on the effects of carbon nanotubes (52) on circulating monocytes (37) and on monocytic (61) and lymphocyte cell lines (65), demonstrating that although they do not exert substantial pro-apoptotic effects, the nanotubes alter the maturation and the activity of macrophages (81). Of particular interest were the cerium oxide nanoparticles (nanoceria), redox-active thanks to their atomic structure and catalytic activity due to the double valence of the cerium atom, which allows extraordinary antioxidant capacities through a redox cycle in which superoxides and peroxides are subsequently eliminated (SOD- and catalase-mimetic activity) self-regenerating the original redox state of the cerium atom, without consumption of biological energy: the model included in a review that has exceeded 800 citations has become a point of reference for those who study the biological effects of nanoceria (78). Nanoceria has proven not only to be biocompatible, but even to exert a cell-protective, anti-apoptotic effect, as demonstrated in a seminal study that is still highly cited (77), which shows that the mechanism underlying the intracellular antioxidant capacity leads to the complete abolition of intrinsic apoptosis (5). In case of apoptosis induced by DNA damage such as UV radiation, the antiapoptotic effect also includes an acceleration of DNA repair, which leads to a dramatic reduction in mutagenicity due to ultraviolet rays (86, X), confirming the redox-sensitive nature of the DNA damage response (79). It should be noted that nanoceria can also counteract the extrinsic apoptotic pathway when it is induced by agents that imply a pro-oxidant action such as TNF (85). The effects of nanoceria on cellular mechanisms were included in a collaborative study with other leading groups in the study of the biological effects of nanoceria worldwide (87).
• Apoptosis in cancer evolution (2015-present)
An innovative in vitro experimental model recapitulating the apoptotic and regenerative phases following chemotherapeutic pro-apoptotic drug administration, allowed detecting stress response, inflammation, epigenetic reprogramming, epithelial-mesenchymal transition, leading to repopulation and acquisition of resistance to apoptosis CRAC (acronym for Cancer Repopulation and Acquired Cell-resistance (113), and metabolic reprogramming [X],. Likewise, hormone-therapy leading to cytostasis revealed the existence of a quasi-apoptotic state (QUAPS) responsible for long-term cancer progression through mobilization of DNA damage (117)
Collaboration with electronic engineers working on 3D cultures, organs-on-chips, machine learning, etc.) allowed addressing the issues of cellular biology not only from the cell-intrinsic point of view (intracellular mechanisms), but also in relation to tissue dynamics (molecular tissue dynamics), permitting exploring the role of apoptosis not only as an intracellular process, but also in the context of a remodeling of the treated tissue (101-103, 107-111, 116, 119).
This attracted the attention of oncologists who performed clinical trials in which biomodulatory drugs were combined with current pro-apoptotic therapies with promising results (93), providing information on new end-points on which to "set" and interpret the experimental and computational part (90, 97, 100, 104, 105), and new ideas for mechanistic analyses (92, 98, 99, 114). This new approach in treating cancer patients is the subject of growing interest, demonstrated by 6 co-managed Special Issues (including editorials in n. 106, 115), and by a series of International Conferences (www.anakoinosis.org).
• Anti-inflammatory effects of cerium oxide nanoparticles (present)
nanoceria would have the ability to be selectively pro-apoptotic in tumor cells, and instead cytoprotective in normal cells, as described in (95). Vvvv In particular, an unexpected and important action of nanoceria is emerging in correcting the altered homeostasis of treated tumor tissues (76, 91, 96), through a detailed modulation of inflammatory parameters (work in preparation). (120)
c) Collaborative studies
Over the years, there have been requests for collaboration from colleagues with different specialties. Problems regarding apoptosis in human macrophages infected with HIV were addressed with infectious disease specialists from the University of Tor Vergata (9, 14); with transfusionists at the S. Orsola Hospital in Bologna, when apoptotic phenomena were characterized in leukocytes present in blood bags for transfusion (17); apoptosis events in leukocytes kept in contact with renal dialysis membranes were studied with nephrologists from the University of Perugia (22, 33). The anti-microbial potential of copper nanoparticles has been investigated with Materials Scientists of the University of Bari for their possible applications against fungi (35) and bacteria (40). The role of lipoxygenase in resistance to apoptosis and tumor progression was investigated together with geneticists from the University of Tuscia (58); with Biochemists of the University of Tor Vergata we studied the mechanism of induction of apoptosis by a new category of anti-tumor drugs such as glutathione-S-transferase inhibitors (39). The mechanisms of activation of the heat-shock response induced by magnetic fields were studied together with pathologists from the University of Parma (51); with biochemists from the University of Urbino the stress response in erythrocytes (16) and the mechanisms of apoptosis in lower eukariot systems (88). Furthermore, the effect of nanoceria on neuronal differentiation was analyzed with toxicologists from the Karolinska Institute, Stockholm, Sweden (94). Finally, with biologists from the Molecular Biology laboratory of the Hopital Kirkberg, Luxembourg, we participated in the analysis of the role of the cyclooxygenase enzyme in the development of tumors (73)

1.2. Organization of Meetings, Workshops and Conferences:
• “APOPTOSIS”, June 1995, Lecce (part of the Organizing Committee)
• 2nd Practical Workshop on Apotosis (European School of Haematology, ESH, and European Cell Death Organization, ECDO) 1998, Lecce: “Relation between Biochemical and Morphological Events” (Lecce 1998) (organizer and chairperson)
• SIGMA-Tau Conference: Apoptosis from biology to clinical medicine (Lecce 1998) (organizer and chairperson)
• XV Italian ADP-ribosylation Group Meeting 2002 (Urbino) organizer and chairperson
• ABCD: XIII Cellular Stress Meeting 2003 (Villa Mondragone) organizer
• 8th International Congress on Amino Acids and Proteins. Rome, Italy, September 5-9, 2003 (organizer and chairperson of the "glutathione" session)
• 7th FISV Conference - Italian Federation of Life Sciences, Riva del Garda (TN) 30 September - 3 October 2004: organizer and chairperson of the Oxidative Stress session
• 7th FISV Conference - Italian Federation of Life Sciences, Riva del Garda (TN), 22-25 September 2005: organizer and chairperson of the Mitochondria and Apoptosis session
• 8th FISV Conference - Italian Federation of Life Sciences, Riva del Garda (TN), 28 September-1 October 2006: organizer and chairperson of the session “in memory of Arturo Leone”.
• 1st international symposium on THERAPEUTIC POTENTIAL OF REDOX ACTIVE NANOPARTICLES AND NATURAL COMPOUNDS Chair: Lina Ghibelli, Rome, April 23, 2014
• Organizer and Chair of the First International Conference on Anakoinosis (Rome) March 2016
• Organizer and Chair of the Second International Conference on Anakoinosis (Rome, www.anakoinosis.org) April 19-20, 2018
• Organizer and chair of the workshop “Applicazioni nanotecnologiche alla Dermatologia” (Rome) October 13th, 2023
Frequent request for session chairing (e.g., ECDO meeting Stockholm 1998; etc)

1.3. Speaker at conferences/meetings
a) Invited speaker at international conferences
• German-Italian workshop on “Apoptosis”, April 1994, Villa Vigoni
• Conference “Cell Death in Human Pathology” June 1995, Lecce
• APOPTOSIS 2003 - From signaling pathways to therapeutic tools. January 29 to Saturday February 1st 2003 European Conference Center-Luxembourg
• 8TH INTERNATIONAL CONGRESS ON AMINO ACIDS AND PROTEINS. Rome, Italy, September 5-9, 2003.
• CELL SIGNALING WORLD 2006 Signal Transduction Pathways as therapeutic targets; Luxembourg, European Conference Center January 25th to 28th, 2006 Kirchberg
• NANOSCIENCE AND NANOTECHNOLOGY 2006 - Villa Mondragone November 5-9 Monte Porzio Catone (Rome), Italy
• NANOSCIENCE AND NANOTECHNOLOGY 2007 - October 15-16, Villa Mondragone, Monte Porzio Catone (Rome), Italy
• APOPTOSIS WORLD 2008, From Mechanisms to Applications, European Conference Center, Luxembourg, January 23rd to January 26th, 2008
• CDD Conference on “Cell stress and apoptosis”, Fisciano (Salerno, I) July 3-4 2008
• 2009 MANA-URTV Joint Workshop at University of Rome Tor Vergata
• XLIII Symposium of your Polish Society for Histochemistry and Cytochemistry, September 21st-23rd, 2009 Bydgoszcz, Poland
• MAC'09: EMBO meeting: “Mitochondria, Apoptosis & Cancer”; 1 - 3 October, 2009 Prague, Czech Republic
• Inflammation 2010 Conference on “Inflammatory cell signaling mechanisms as therapeutic targets”, 27-30 January 2010, Luxembourg.
• 1st Italian-Swedish Workshop on “Health Impacts of Engineered Nanomaterials”, Tor Vergata University, Rome, Italy, October 14-15, 2010
• "International Symposium on the Social Acceptance of Nanomaterials", 20th MRS-Japan Academic Symposium, Yokohama, December 20-22, 2010
• 2012 Redox and Inflammation signaling 2012 - RedCat Meeting on “Redox Catalysis from Chemistry to Biology” (Luxembourg, January 25th to 27th, 2012).
• Symposium "Rare-Earth-based Materials", 2012 Spring Meeting of the Materials Research Society, S. Francisco, April 9-13, 2012.
• 2nd Italian-Swedish Workshop on “Health Impacts of Engineered Nanomaterials”, Karolinska Institutet, June 14-16 2012, Stockholm, Sweden
• NATO HFM-223 Symposium on "Biological Effects of Ionizing Radiation Exposure and Countermeasures: Current Status and Future Perspectives", Ljubljana, October 7-10, 2012
• FASEB International Conference “Melatonin Biology: actions and therapeutics” Lisbon, Portugal, July 19-24, 2015
• ‘Innovative Approaches to Explore Novel Druggable Targets’, Seoul National University Cancer Research Institute (SNU CRI) Annual Symposium 1st to 4th April, 2015 (South Korea)
• German-Italian workshop on “Cell Death in Neurodegeneration, Inflammation and Cancer”, Villa Vigoni, June 24-27, 2015
• International Symposium on The Future of Regenerative Medicine, Tuscania, Italy (October 5-6 2017)
• 6th International Meeting on Metronomic Chemotherapy in Oncology, October 1-2, 2018, Grand Rapids, Michigan (USA)
• Italian Embassy in Tokyo: Webinar Italy-Japan approaches for emerging alternative cancer therapies. Tokyo, October 21th 2021
• New approaches for safety and sustainability: from nanomaterials to advanced and innovative (nano)materials (Rome) October 18th 2022
b) Invited speaker at Italian Meeting
• workshop: “Relazione tra struttura e funzioni nel nucleo della cellula” Convegno Società Italiana Microscopia Elettronica, Lecce, 1996
• Apoptosi1997, 13 Novembre 1997, Università di Parma
• Apoptosi 2000, 30 Marzo 2000, Università di Parma
• Convegno Società Italiana Scienze Microscopiche, Urbino, 2003
• AICC Convegno Associazione Italiana Colture Cellulari: La morte della Cellula, Firenze 2-4 Dicembre 2009
• “Nanoforum” 2014, Università La Sapienza Roma, 22-25 Settembre 2014
• “Nuclear structure and dynamics through the microscopes”, (Società Italiana di Scienze Microscopiche (SISM) e Società Italiana di Istochimica, Pavia 7-8 luglio 2016.
c) Selected speaker in International Conferences
• 11th International Symposium on ADP-ribosylation: DNA Repair, Signal Transduction, Sept. 17-21, 1994, Strasbourg-Bischenberg, France
• Second International Symposium on Nanotechnology and Occupational Health, October 3-6, 2005, Minneapolis, MN USA
• 5th International Conference on Na/Ca exchange, August 23-27, 2006 Brussels
• Second Nanotoxicology Conference, April 19-21, 2007, Venice (I)
• ABCAM meeting: “Apoptosis and Cancer: The Bcl-2 family of proteins”, June 25-26, 2009 - Dartmouth College, NH (USA)
• Metabolism 2014 – “Alterations of metabolic pathways as therapeutic targets” January 29-31, 2014, Esch-sur-Alzette, Luxembourg.
• International Cancer Microenvironment Society: 8th International Conference on Tumor Microenvironment “Progression, therapy and prevention”, Lisbon, Portugal, June 10-14, 2018

1.4. Invited Seminars:
• 1994 Hopital Saint-Louis (Paris, F) Dr. Michel Lanotte
• 1995 Karolinska Insitutet (Stockholm, SW) Prof. Sten Orrenius
• 2001 University of Guilford (Surrey, UK) Prof. Georges Kass
• 2005 National Institute of Health (Bethesda, MD, USA) Dr. Robert Youle
• 2005 MD Anderson Cancer Center, Houston (TX, USA) Dr. Raymond Meyn
• 2006 LBMCC, Hopital Kirchberg (Luxembourg) Prof. Marc Diederich
• 2010 National Institute for Materials Science (Tsukuba, JP) Prof. Enrico Traversa
• 2010 University of Tsukuba (Tsukuba, JP) Prof. Nagasaki
• 2011 LBMCC, Hopital Kirchberg (Luxembourg) Prof. Marc Diederich
• 2014 KAUST (Saudi Arabia) Prof. Enrico Traversa
• 2015 University Hospital Regensburg (Regensburg, Germany) Prof. Albrecht Reichle
• 2019 RIKEN, Tokyo (Japan) prof. Piero Carninci
• 2019 National Cancer Center Research Institute Tokyo (Japan) Prof. Rieko Ohki
• 2019 Regina Elena Cancer Institute (Rome) prof. Gennaro Ciliberto
• 2023 Mainz Universtity (D) prof. Ralf Heermann
and in addition:
1991 National Institute of Health (Dr. I. De Angelis); 1994 National Nutrition Institute (Dr. S. Caetani); 1994 University of Bologna (Prof. M. Marini); 1995 University of Lecce (Prof. Dini); 1995 University of Pavia (Prof. C. Pellicciari); 6 seminars at the University of Urbino (1994 Prof. O. Cantoni; 1998 Prof. M. Dachà; 2006 Prof. A. Accorsi; 2007 Prof. Stocchi; 2015 Prof. E. Falcieri; 2019 Prof. MC Albertini); 2000 Regina Elena Cancer Institute, Rome (prof. G. Zupi); 2000 EMBL Monterotondo (Dr. Witke); 3 University of Parma (1998 Prof. G. Guidotti; 2007 and 2008 Prof. P. Petronini); 1999 University of Naples Federico II (Prof. B. Farina); 1999 ENEA Casaccia, Anguillara (Dr. A. Giovanetti); 2006 University of Tuscia (Prof. Merendino); 2006 Polytechnic University of Marche (Prof. A. Procopio); 2010 University of Pisa (Prof. A. Pompella); 2012 S. Gallicano Hospital, Rome (Dr. V. Maresca)

1.5. Main Scientific Collaborations documented by Joint Publications
At the University of Rome Tor Vergata: Prof. MR Ciriolo; Prof. E Traversa; Prof. AM Caccuri; Prof. A. Magrini; Prof. C Pesce; Prof. S. Licoccia; Prof. E. Martinelli; Prof. J. Pedersen; Prof. E. Bonanno, Prof. F. Torino; Prof. D.O. Cicero
In Italy: Prof. G Gualandi (University of Tuscia); Prof. PG Petronini (University of Parma); Prof. A Accorsi (University of Urbino, Institute of Biological Chemistry); Prof. P Sestili (University of Urbino, Institute of Pharmacology); Prof. G Tarzia (University of Urbino, Institute of Pharmaceutical Chemistry); Dr. AI Scovassi (Institute of Molecular Genetics CNR Pavia); Prof. V Vullo (La Sapienza University of Rome, Department of Infectious Diseases); Prof LM Porfiri (La Sapienza University of Rome, Department of Radiology); Dr. A. Giovanetti (ENEA); Dr. V. Maresca (S. Gallicano Hospital); Dr. L. Teodori (ENEA); DR. C.M. Failla (IDI) Roma
Abroad: Prof. T. McDonnell (MD Anderson Cancer Center, Houston TX USA); Dr. M. Diederich (Hopital Kirchberg Luxembourg); Prof. A. Reichle (University Hospital Regensburg, Regensburg, Germany); Dr. P. Pantziarka (Anticancer Fund, Brussels, Belgium); Prof. B. Fadeel (Karolinska Institute, Stockholm, Sweden); Prof. F. Stellacci (EPFL, Lausanne, Switzerland); Prof. A. Grzanka (Nicolaus Copernicus University, Bydgoszcz, Poland); Prof. S. Seal (University of Central Florida, FL, USA); Prof. J. Erlichman (St. Lawrence University, Canton, NY, USA); Prof. I. Bejarano (University of Sevilla, Spain)

1.7. Editorial Activities
1.7.1. Associate Editor:
• Frontiers in Pharmacology
• International Journal Molecular Science
• Advances in Redox Research
• Conference Papers in Pharmacology
1.7.2. Guest Editor:
• 2011 Special Issue "Organelle cross-talk in apoptotic and survival pathways", International Journal of Cell Biology
• MRS Bulletin November 2014 “Biological interaction of oxide nanoparticles”
• 2018 Research Topic in Frontiers in Pharmacology “ANAKOINOSIS - Re-Establishing Apoptosis Competence via Communicative Reprogramming” (https://www.frontiersin.org/research-topics/7413/)
• 2019 Special issue “Systems Biologic Implications of Metronomic Therapies in Cancer and Hematologic Neoplasia” Intern. J. Molecular Science (http://www.mdpi.com/journal/ijms/special_issues/metronomic_therapies).
• 2019 Research Topic in Frontiers in Oncology “Tumor Systems Biology: How To Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e. Anakoinosis)” https://www.frontiersin.org/research-topics/9530/tumor-systems-biology-how-to-therapeutically-redirect-dysregulated-homeostasis-in-tumor-systems-ie-a
• 2020 Research Topic in Frontiers in Pharmacology “Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis”

1.7.3. Peer Review:
• FASEB Journal, Biochemical Pharmacology, FEBS, Toxicology and Applied Pharmacology, Experimental Cell Research, Toxicology, Leukemia, Bioelectromagnetic, Archives Biochemistry Biophysics, BBA, Drug Development Research, Antiviral Therapy, Journal of Nanoparticle Research, etc. Peer reviewer of grant proposals (Italia: PRIN; FIRB; Universita' di Siena. Abroad: Private foundations in UK, F, L)

2. TEACHING ACTIVITY:
Front teaching:
• 1984-1998: support for "Genetics", Department of Biology, University of Rome Tor Vergata (Prof. Calef and Prof. Cesareni)
• 1998-2002: responsible for the "General Pathology" course, Faculty of Pharmacy, University of Urbino (MED04)
• 2005-2010: responsible for the "Applied Biology" course, "Prevention Technicians" school, Faculty of Medicine, University of Rome Tor Vergata (1 credit)
• 2003-2007: responsible for the "Biology" course, School of specialization in Occupational Medicine, Faculty of Medicine, University of Rome Tor Vergata
• 2003-2010 responsible for the course "Cellular Stress", Master's Degree in Cellular and Molecular Biology, University of Rome Tor Vergata
• 2010-2014: responsible for the course "Signaling, Stress and Apoptosis", Master's Degree in Bioinformatics, University of Rome Tor Vergata (BIO13; 6 credits)
• 2010-2011: "Applied Biology" in "Integrated Cellular and Molecular Biology Course, University of Rome Tor Vergata
• 2014-present: responsible for the Nanobiotechnology course, Master's Degree Course in Biotechnology (in English), University of Rome Tor Vergata
• 2014-present: teaching assignment at Our Lady of Good Counsel University, Tirana (Albania)
• School of Biotechnology and Experimental Oncology, Genoa, 1996: Lecturer of "Proliferation and cell death" (Genoa 1996)
Supervisor activities:
• 6 Pharmacy theses (non-experimental, University of Urbino)
• 6 bachelor theses in Biology (experimental)
• 29 Master theses (experimental):
Biology University of Roma Tre (external supervisor) (1); in Materials Sciences, University of Rome Tor Vergata (external supervisor) (1).
University of Urbino: Degree course in Pharmacy, (1); University of Tor Vergata: Degree in Old Order Biology (12), Master's Degree in Bioinformatics (3), Specialist/Master's Degrees in Cellular and Molecular Biology (3); Master's Degree in Evolutionary Biology (2); Master's Degree in Biotechnology/Biotechnology (5)
• 21 PhD theses:
Two specialization theses in Biotechnology (Dep. Biology, Tor Vergata); 16 in University of Tor Vergata (7 in Materials for Health Energy and Environment; 1 in Biopathology; 1 in Cellular and Evolutionary Biology; 9 in Cellular and Molecular Biology; plus co-supervisor of 3 PhD foreign students for internationalization (Spain (2); Iran)
Mentorship:
Former students who have undertaken research activities (type and period of mentorship):
• Simona Coppola (Master degree in Biology 1993 and PhD Cellular and Molecular Biology 1998), now Researcher at the Istituto Superiore di Sanità, H-index = 25)
• Vittoria Maresca (Specialization in Biotechnology 1996), now Researcher at IRCCS San Gallicano Dermatological Institute, Rome (H-index = 27)
• Claudia Colussi (Master thesis in Biology 1996) now Researcher at Fondazione Policlinico Universitario Agostino Gemelli IRCCS, (H-index = 26)
• Claudia Cerella (Master and PhD in Biology 1999), now Group Leader at LBMCC, Hopital Kirkberg, Luxembourg (H-index = 36)
• Flavia Radogna (Master's Thesis and PhD in Biology 2005, PhD Cellular and Molecular Biology 2009), now Researcher at LBMCC, Hopital Kirkberg, Luxembourg (H-index = 22)
• Silvia Cristofanon (Master's Thesis and PhD in Biology 2004, PhD in Cellular and Molecular Biology 2008), now Research Fellow at the European Institute of Oncology, Milan (H-index = 23)
• Sonia Cordisco (Master's Thesis in Biology 2004), now Researcher at IRCCS Istituto Dermopatico dell'Immacolata, Rome (H-index = 9)
• Giovanna Clavarino (Master thesis in Biology 2004 ), now Researcher at Centre Hospitalier Universitaire de Grenoble, France (H-index = 16)
• Ivana Celardo (PhD in Cellular and Molecular Biology 2011) now Research Fellow University of Konstanz, Germany (H-index = 13)
• Rolando Vegliante (Master thesis in Biology) now Researcher at Université Libre de Bruxelles (H-index = 12)
• Fanny Caputo (Master and PhD thesis in Materials Science 2011 and PhD in Materials for Health, Environment and Energy 2015) now Researcher at SINTEF Foundation, Trondheim, Norway (H-index = 20)
• Ignacio Bejarano (post-doc 2013-2015) now Associate Professor University of Sevilla (H index = 26)
• Simone Gardini (Degree in Bioinformatics 2015) now Director and Founder of the Startup “GenomeUP” (H-index = 8)
• Fabiana Martino (Bachelor's Degree in Biotechnology 2015) now Research Fellow at the Competence Center for Mechanobiology in Regenerative Medicine, Brno, Czech Republic (H-index = 6)
• Francesca Corsi (PhD in Materials for Health Energy and Environment, 2020) now Research Fellow at Tor Vergata (H-index = 7)

2.4. Commissioner activities
a) thesis/doctoral defences
• >10 doctoral commissions: (2 University of Tuscia; 1 University of Parma; 2 University of Urbino, 1 University of Rome Tor Vergata (Materials for Health, Environment and Energy), 3 Université de Nancy (F); 1 Université de Nantes (F).
- regular member of Graduation Commissions (Tor Vergata; Pharmacy in Urbino (1998-2002)
b) Competitions
• 6 chairmanships of Research Grants Commission
• 5 presidencies of Scholarship Commission
• 1 Commission Presidency for fixed-term researcher position type b (2019)

2.5. Academic Advice
• Member of the Doctorate collegium of the PhD course in Cellular and Molecular Biology, Department of Biology, University of Rome Tor Vergata (1995-2017)
• Member of the Doctorate collegium of the PhD Course in Evolutionary Biology, Department of Biology, University of Rome Tor Vergata (2017-2020)
• Member of the Doctorate collegium of the PhD Course in Materials for Sustainable Development, Department of Chemical Sciences and Technologies, University of Rome Tor Vergata (presently)
• Master’s School in Biology, Tor Vergata (1984-2008)
• Master's School in Bioinformatics University of Rome Tor Vergata (2008-2014)
• Master's School in Biotechnology, University of Rome Tor Vergata (2014-2023)

3. FUNDED RESEARCH PROJECTS
Research projects admitted to funding on the basis of competitive calls
• 1997, National Research Council, Strategic Project 'Cell Cycle and Apoptosis', participant (national coordinator Prof. Maria Ciriolo, University of Chieti)
• 1998 “Blood Project”, Istituto Superiore di Sanità participant (National Coordinator Prof. R. Conte, Policlinico S. Orsola, Bologna)
• PRIN 2002: “Role of melatonin in the control of apoptosis: morphological, biochemical aspects and pharmacological perspectives” (Unit coordinator)
• PRIN 2003: “Impact of nanotubes on human health” (Unit coordinator)
• PRIN 2008: “miRNA in the diagnosis and experimental therapy mediated by nanovectors of malignant pleural mesothelioma” (Unit coordinator)
• 2017 University project “Tissue engineering to study myelination processes”, participant (coordinator Prof. Enrico Traversa)
• 2019 BEYOND BORDERS Tor Vergata, “Cancer repopulation and acquired chemo-resistance: a three-dimensional approach”, Principal Investigator
• 2021 Lazio Region Research Group Project, “PANACERIA: Prevention and treatment of dermatological pathologies using nanoceria”, Principal Investigator

Peer reviewed publications on international journals indexed in Scopus/ISI databases
 
1. Ghibelli L, Usala SJ, Mukhopadhyay R, Haselkorn R.
Polyadenylation and reverse transcription of bacteriophage phi 6 double-stranded RNA.
Virology. 1982 30;120:318-28.
 
2. Civitareale D, Ghibelli L, Di Lauro R.
Partial purification of a thyroid specific nuclear protein recognizing the thyroglobulin
promoter.
Horm Metab Res Suppl. 1987; 17:73-7.
 
3. Sinclair AJ, Lonigro R, Civitareale D, Ghibelli L, Di Lauro R.
The tissue-specific expression of the thyroglobulin gene requires interaction between
thyroid-specific and ubiquitous factors.
Eur J Biochem. 1990; 193:311-8.
 
4. Piacentini M, Autuori F, Dini L, Farrace MG, Ghibelli L, Piredda L, Fesus L.
"Tissue" transglutaminase is specifically expressed in neonatal rat liver cells
undergoing apoptosis upon epidermal growth factor-stimulation.
Cell Tissue Res. 1991; 263:227-35.
 
5. Piacentini M, Fesus L, Farrace MG, Ghibelli L, Piredda L, Melino G.
The expression of "tissue" transglutaminase in two human cancer cell lines is related
with the programmed cell death (apoptosis).
Eur J Cell Biol. 1991; 54:246-54.
 
6. Ghibelli L, Nosseri C, Oliverio S, Piacentini M, Autuori F.
Cycloheximide can rescue heat-shocked L cells from death by blocking stress-induced
apoptosis.
Exp Cell Res. 1992; 201:436-43.
 
7. Nosseri C, Coppola S, Ghibelli L.
Possible involvement of poly(ADP-ribosyl) polymerase in triggering stress-induced
apoptosis.
Exp Cell Res. 1994; 212:367-73.
 
8. Ghibelli L, Coppola S, Nosseri C, Bergamini A, Beninati S.
A protein produced by a monocytic human cell line can induce apoptosis on tumor cells.
FEBS Lett. 1994; 344:35-40.
 
9. Bergamini A, Capozzi M, Ghibelli L, Dini L, Salanitro A, Milanese G, Wagner T,
Beninati S, Pesce CD, Amici C, Rocchi G.
Cystamine potently suppresses in vitro HIV replication in acutely and chronically
infected human cells.
J Clin Invest. 1994; 93:2251-7.
 
10. Coppola S, Nosseri C, Maresca V, Ghibelli L.
Different basal NAD levels determine opposite effects of poly(ADP-ribosyl)polymerase inhibitors on H2O2-induced apoptosis.
Exp Cell Res. 1995; 221:462-9.

11. Ghibelli L, Nosseri C, Coppola S, Maresca V, Dini L.
The increase in H2O2-induced apoptosis by ADP-ribosylation inhibitors is related to cell blebbing.
Exp Cell Res. 1995; 221:470-7.
 
12. Ghibelli L, Maresca V, Coppola S, Gualandi G.
Protease inhibitors block apoptosis at intermediate stages: a compared analysis of DNA fragmentation and apoptotic nuclear morphology.
FEBS Lett. 1995; 377:9-14.
 
13. Ghibelli L, Coppola S, Rotilio G, Lafavia E, Maresca V, Ciriolo MR.
Non-oxidative loss of glutathione in apoptosis via GSH extrusion.
Biochem Biophys Res Commun. 1995; 216:313-20.
 
14. Bergamini A, Dini L, Capozzi M, Ghibelli L, Placido R, Faggioli E, Salanitro A,
Bonanno E, Cappannoli L, Ventura L, Cepparulo M, Falasca L, Rocchi G.
Human immunodeficiency virus-induced cell death in cytokine-treated macrophages can be prevented by compounds that inhibit late stages of viral replication.
J Infect Dis. 1996; 173:1367-78.
 
15. Dini L, Coppola S, Ruzittu MT, Ghibelli L.
Multiple pathways for apoptotic nuclear fragmentation.
Exp Cell Res. 1996; 223:340-7.
 
16. Albertini MC, Ghibelli L, Ricciotti R, Fumelli C, Canestrari F, Galli F, Rovidati S, Bonanno E, Fumelli P
Morphological alterations and increased resistance to hemolysis in t-butyl hydroperoxide incubated RBC from elderly subjects
Archives of Gerontology and Geriatrics 22 (SUPPL.1), 1996,423-428
 
17. Frabetti F, Musiani D, Marini M, Fanelli C, Coppola S, Ghibelli L, Tazzari PL,
Bontadini A, Tassi C, Conte R.
White cell apoptosis in packed red cells.
Transfusion. 1998; 38:1082-9.
 
18. Galli F, Rovidati S, Ghibelli L, Canestrari F.
S-nitrosylation of glyceraldehyde-3-phosphate dehydrogenase decreases the enzyme affinity to the erythrocyte membrane.
Nitric Oxide. 1998; 2:17-27.
 
19. Ghibelli L, Fanelli C, Rotilio G, Lafavia E, Coppola S, Colussi C, Civitareale P,
Ciriolo MR.
Rescue of cells from apoptosis by inhibition of active GSH extrusion.
FASEB J. 1998; 12:479-86.
 
20. Fanelli C, Coppola S, Barone R, Colussi C, Gualandi G, Volpe P, Ghibelli L.
Magnetic fields increase cell survival by inhibiting apoptosis via modulation of Ca2+ influx.
FASEB J. 1999; 13:95-102.

21. Ghibelli L, Coppola S, Fanelli C, Rotilio G, Civitareale P, Scovassi AI, Ciriolo MR.
Glutathione depletion causes cytochrome c release even in the absence of cell commitment to apoptosis.
FASEB J. 1999 13:2031-6.
 
22. Buoncristiani U, Galli F, Benedetti S, Errico R, Beninati S, Ghibelli L, Floridi A, Canestrari F.
Quantitative and qualitative assessment and clinical meaning of molecules removed with BK membranes.
Contrib Nephrol. 1999; 125:133-58. Review.
 
23. Colussi C, Albertini MC, Coppola S, Rovidati S, Galli F, Ghibelli L.
H2O2-induced block of glycolysis as an active ADP-ribosylation reaction protecting cells
from apoptosis.
FASEB J. 2000 14:2266-76.
 
24. Coppola S, Ghibelli L.
GSH extrusion and and the mitochondrial pathway of apoptotic signalling.
Biochem Soc Trans. 2000 2:56-61. Review.
 
25. Teodori L, Göhde W, Valente MG, Tagliaferri F, Coletti D, Perniconi B, Bergamaschi A, Cerella C, Ghibelli L.
Static magnetic fields affect calcium fluxes and inhibit stress-induced apoptosis in human glioblastoma cells.
Cytometry. 2002; 49:143-9.
 
26. Teodori L, Grabarek J, Smolewski P, Ghibelli L, Bergamaschi A, De Nicola M, Darzynkiewicz Z.
Exposure of cells to static magnetic field accelerates loss of integrity of plasma
membrane during apoptosis.
Cytometry. 2002; 49:113-8.
 
27. D'Alessio M, Cerella C, De Nicola M, Bergamaschi A, Magrini A, Gualandi G, Alfonsi AM, Ghibelli L.
Apoptotic GSH extrusion is associated with free radical generation.
Ann N Y Acad Sci. 2003; 1010:449-52.
 
28. Liuzzi F, Fanelli C, Ciriolo MR, Cerella C, D'Alessio M, Denicola M, Magrini A, Bergamaschi A, Ghibelli L.
Rescue of cells from apoptosis by antioxidants occurs downstream from GSH extrusion.
Ann N Y Acad Sci. 2003; 1010:441-5.
 
29. De Nicola M, Liuzzi F, Cerella C, D'Alessio M, Bergamaschi A, Magrini A, Ghibelli L.
Hypoxic stress stably alters apoptotic parameters on U937 cells.
Ann N Y Acad Sci. 2003; 1010:426-9.
 
30. Cerella C, D'Alessio M, De Nicola M, Magrini A, Bergamaschi A, Ghibelli L.
Cytosolic and endoplasmic reticulum Ca2+ concentrations determine the extent and the morphological type of apoptosis, respectively.
Ann N Y Acad Sci. 2003; 1010:74-7.

31. Ghibelli L, Teodori L, Cerella C, De Nicola M, D'Alessio M, Clavarino G, Cordisco S, Albertini MC, Accorsi A, Magrini A, Bergamaschi A.
Epigenetic role of magnetic field exposure in tumor progression: fine-tuning experimental models
G Ital Med Lav Ergon. 2003; 25 Suppl(3):277-8.
 
32. Ghibelli L, Mengoni F, Lichtner M, Coppola S, De Nicola M, Bergamaschi A, Mastroianni C, Vullo V.
Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain.
Biochem Pharmacol. 2003; 66:1505-12.
 
33. Galli F, Ghibelli L, Buoncristiani U, Bordoni V, D'Intini V, Benedetti S, Canestrari F, Ronco C, Floridi A.
Mononuclear leukocyte apoptosis in haemodialysis patients: the role of cell thiols and vitamin E.
Nephrol Dial Transplant. 2003; 18:1592-600.
 
34. Honda T, Coppola S, Ghibelli L, Cho SH, Kagawa S, Spurgers KB, Brisbay SM, Roth JA, Meyn RE, Fang B, McDonnell TJ.
GSH depletion enhances adenoviral Bax-induced apoptosis in lung cancer cells.
Cancer Gene Ther. 2004; 11:249-55.
 
35. Cioffi N, Torsi L, Ditaranto N, Sabbatini L, Zambonin PG, Tantillo G, Ghibelli L, D'Alessio M
Antifungal activity of polymer-based copper nanocomposite coatings
Appl. Phys. Lett. 2004; 85:2417 DOI:10.1063/1.1794381
 
36. D'Alessio M, Cerella C, Amici C, Pesce C, Coppola S, Fanelli C, De Nicola M, Cristofanon S, Clavarino G, Bergamaschi A, Magrini A, Gualandi G, Ghibelli L.
Glutathione depletion up-regulates Bcl-2 in BSO-resistant cells.
FASEB J. 2004; 18:1609-11.
 
37. Ghibelli L, De Nicola M, Somma G, Cerella C, D'Alessio M, Romeo E, Magrini A, Bergamaschi A.
Lack of direct cytotoxic effect of intracellular nanotubes
G Ital Med Lav Ergon. 2005; 27:383-4.
 
38. D'Alessio M, De Nicola M, Coppola S, Gualandi G, Pugliese L, Cerella C, Cristofanon S, Civitareale P, Ciriolo MR, Bergamaschi A, Magrini A, Ghibelli L.
Oxidative Bax dimerization promotes its translocation to mitochondria independently of apoptosis.
FASEB J. 2005; 19:1504-6.
 
39. Turella P, Cerella C, Filomeni G, Bullo A, De Maria F, Ghibelli L, Ciriolo MR, Cianfriglia M, Mattei M, Federici G, Ricci G, Caccuri AM.
Proapoptotic activity of new glutathione S-transferase inhibitors.
Cancer Res. 2005; 65:3751-61.
 
40. Cioffi N, Torsi L, Ditaranto N, Tantillo G, Ghibelli L, Sabbatini L, Bleve-Zacheo T, D'Alessio M, Zambonin PG, Traversa E
Copper Nanoparticle/Polymer Composites with Antifungal and Bacteriostatic Properties
Chem. Mater., 2005 17 (21), 5255 ‘5262

41. Radogna F, Paternoster L, Albertini MC, Accorsi A, Cerella C, D'Alessio M, De Nicola M, Nuccitelli S, Magrini A, Bergamaschi A, Ghibelli L.
Melatonin as an apoptosis antagonist.
Ann N Y Acad Sci. 2006; 1090:226-33.
 
42. Nuccitelli S, Cerella C, Cordisco S, Albertini MC, Accorsi A, De Nicola M, D'Alessio M, Radogna F, Magrini A, Bergamaschi A, Ghibelli L.
Hyperpolarization of plasma membrane of tumor cells sensitive to antiapoptotic effects of magnetic fields.
Ann N Y Acad Sci. 2006; 1090:217-25.
 
43. De Nicola M, Cerella C, D'Alessio M, Coppola S, Magrini A, Bergamaschi A, Ghibelli L.
The cleavage mode of apoptotic nuclear vesiculation is related to plasma membrane blebbing and depends on actin reorganization.
Ann N Y Acad Sci. 2006; 1090:69-78.
 
44. De Nicola M, Cordisco S, Cerella C, Albertini MC, D'Alessio M, Accorsi A, Bergamaschi A, Magrini A, Ghibelli L.
Magnetic fields protect from apoptosis via redox alteration.
Ann N Y Acad Sci. 2006; 1090:59-68.
 
45. Cerella C, Mearelli C, Ammendola S, De Nicola M, D'Alessio M, Magrini A, Bergamaschi A, Ghibelli L.
Molecular determinants involved in the increase of damage-induced apoptosis and delay of secondary necrosis due to inhibition of mono(ADP-ribosyl)ation.
Ann N Y Acad Sci. 2006; 1090:50-8.
 
46. Albertini MC, Radogna F, Accorsi A, Uguccioni F, Paternoster L, Cerella C, De Nicola M, D'Alessio M, Bergamaschi A, Magrini A, Ghibelli L.
Intracellular pro-oxidant activity of melatonin deprives U937 cells of reduced glutathione without affecting glutathione peroxidase activity.
Ann N Y Acad Sci. 2006; 1091:10-6.
 
47. Cristofanon S, Nuccitelli S, D'Alessio M, Radogna F, De Nicola M, Bergamaschi A, Cerella C, Magrini A, Diederich M, Ghibelli L.
Oxidative upregulation of Bcl-2 in healthy lymphocytes.
Ann N Y Acad Sci. 2006; 1091:1-9.
 
48. De Nicola M, Gualandi G, Alfonsi A, Cerella C, D'Alessio M, Bergamaschi A, Magrini A, Ghibelli L.
Different fates of intracellular glutathione determine different modalities of apoptotic nuclear vesiculation.
Biochem Pharmacol. 2006; 72:1405-16.
 
49. Ghibelli L, Cerella C, Cordisco S, Clavarino G, Marazzi S, De Nicola M, Nuccitelli S, D'Alessio M, Magrini A, Bergamaschi A, Guerrisi V, Porfiri LM.
NMR exposure sensitizes tumor cells to apoptosis.
Apoptosis. 2006; 11:359-65.
50. Lichtner M, Mengoni F, Mastroianni CM, Sauzullo I, Rossi R, De Nicola M, Vullo V, Ghibelli L.
HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition.
Apoptosis. 2006; 11:781-7.

51. Alfieri RR, Bonelli MA, Pedrazzi G, Desenzani S, Ghillani M, Fumarola C, Ghibelli L, Borghetti AF, Petronini PG.
Increased levels of inducible HSP70 in cells exposed to electromagnetic fields.
Radiat Res. 2006; 165:95-104.
 
52. De Nicola M, Mirabile Gattia D, Bellucci S, De Bellis G, Micciulla F, Pastore R, Tiberia A, Cerella C, D'Alessio M, Vittori Antisari M, Marazzi R, Traversa E, Magrini A, Bergamaschi A, Ghibelli L
Effect of different carbon nanotubes on cell viability and proliferation
J. Phys.: Condens. Matter 2007 19 395013 (7pp)  doi: 10.1088/0953-8984/19/39/395013
 
53. Cerella C, Mearelli C, Coppola S, D'Alessio M, De Nicola M, Diederich M, Ghibelli L.
Sequential phases of Ca2+ alterations in pre-apoptotic cells.
Apoptosis. 2007; 12:2207-19.
 
54. Radogna F, Paternoster L, Albertini MC, Cerella C, Accorsi A, Bucchini A, Spadoni G, Diamantini G, Tarzia G, De Nicola M, D'Alessio M, Ghibelli L.
Melatonin antagonizes apoptosis via receptor interaction in U937 monocytic cells.
J Pineal Res. 2007; 43:154-62.
 
55. Dorio A, Cerella C, De Nicola M, D'Alessio M, Gualandi G, Ghibelli L.
Non-apoptogenic Ca2+-related extrusion of mitochondria in anoxia/reoxygenation stress.
Ann N Y Acad Sci. 2007; 1099:512-5.
 
56. Cerella C, Mearelli C, De Nicola M, D'Alessio M, Magrini A, Bergamaschi A, Ghibelli L.
Analysis of calcium changes in endoplasmic reticulum during apoptosis by the fluorescent indicator chlortetracycline.
Ann N Y Acad Sci. 2007; 1099:490-3.
 
57. Cerella C, Coppola S, D'Alessio M, De Nicola M, Magrini A, Bergamaschi A, Ghibelli L.
Redox modulation of the apoptogenic activity of thapsigargin.
Ann N Y Acad Sci. 2007; 1099:469-72.
 
58. Belfiore MC, Natoni A, Barzellotti R, Merendino N, Pessina G, Ghibelli L, Gualandi G.
Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted B lymphoma cells.
Cancer Lett. 2007; 254:236-43.
 
59. Radogna F, Cristofanon S, Paternoster L, D'Alessio M, De Nicola M, Cerella C, Dicato M, Diederich M, Ghibelli L.
Melatonin antagonizes the intrinsic pathway of apoptosis via mitochondrial targeting of Bcl-2.
J Pineal Res. 2008; 44:316-25.
60. Cristofanon S, Nuccitelli S, D'Alessio M, Dicato M, Diederich M, Ghibelli L.
Oxidation-dependent maturation and survival of explanted blood monocytes via Bcl-2 up-regulation.
Biochem Pharmacol. 2008; 76:1533-43.

61. Milena De Nicola, Stefano Bellucci, Enrico Traversa, Federico Micciulla and Lina Ghibelli.
Carbon Nanotubes On Jurkat Cells: Effects On Cell Viability And Plasma Membrane Potential.
Journal of Physics: Condensed Matter, 2008 Vol. 20, Issn: 0953-8984
 
62. Cristofanon S, Morceau F, Scovassi AI, Dicato M, Ghibelli L, Diederich M.
Oxidative, multistep activation of the noncanonical NF-kappaB pathway via disulfide Bcl-3/p50 complex.
FASEB J. 2009; 23:45-57.
 
63. Radogna F, Paternoster L, De Nicola M, Cerella C, Ammendola S, Bedini A, Tarzia G, Aquilano K, Ciriolo M, Ghibelli L.
Rapid and transient stimulation of intracellular reactive oxygen species by melatonin in normal and tumor leukocytes.
Toxicol Appl Pharmacol. 2009 238:161-169.
 
64. Radogna F, Sestili P, Martinelli C, Paolillo M, Paternoster L, Albertini MC, Accorsi A, Gualandi G, Ghibelli L.
Lipoxygenase-mediated pro-radical effect of melatonin via stimulation of arachidonic acid metabolism.
Toxicol Appl Pharmacol. 2009; 238:170-7.
 
65. De Nicola M, Nuccitelli S, Gattia DM, Traversa E, Magrini A, Bergamaschi A, Ghibelli L.
Effects of carbon nanotubes on human monocytes.
Ann N Y Acad Sci. 2009; 1171:600-5.
 
66. Cerella C, D'Alessio M, Cristofanon S, De Nicola M, Radogna F, Dicato M, Diederich M, Ghibelli L.
Subapoptogenic oxidative stress strongly increases the activity of the glycolytic key enzyme glyceraldehyde 3-phosphate dehydrogenase.
Ann N Y Acad Sci. 2009; 1171:583-90.
 
67. Cerella C, Coppola S, Maresca V, De Nicola M, Radogna F, Ghibelli L.
Multiple mechanisms for hydrogen peroxide-induced apoptosis.
Ann N Y Acad Sci. 2009; 1171:559-63.
 
68. Radogna F, Nuccitelli S, Mengoni F, Ghibelli L.
Neuroprotection by melatonin on astrocytoma cell death.
Ann N Y Acad Sci. 2009; 1171:509-13.
 
69. Cristofanon S, Uguccioni F, Cerella C, Radogna F, Dicato M, Ghibelli L, Diederich M.
Intracellular prooxidant activity of melatonin induces a survival pathway involving NF-kappaB activation.
Ann N Y Acad Sci. 2009; 1171:472-8.
 
70. Paternoster L, Radogna F, Accorsi A, Albertini MC, Gualandi G, Ghibelli L.
Melatonin as a modulator of apoptosis in B-lymphoma cells.
Ann N Y Acad Sci. 2009; 1171:345-9.

71. Ghibelli L, Diederich M.
Multistep and multitask Bax activation.
Mitochondrion. 2010; 10:604-13.
 
72. Radogna F, Diederich M, Ghibelli L
Melatonin: a pleiotropic molecule regulating inflammation.
Biochem Pharmacol. 2010; 80:1844-52.
 
73. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M.
The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies.
Int J Cell Biol. 2010; 215158.
 
74. Cerella C, Diederich M, Ghibelli L.
The dual role of calcium as messenger and stressor in cell damage, death, and survival.
Int J Cell Biol. 2010; 546163.
 
75. Cerella C, Cordisco S, Albertini MC, Accorsi A, Diederich M, Ghibelli L.
Magnetic fields promote a pro-survival non-capacitative Ca(2+) entry via phospholipase C signaling.
Int J Biochem Cell Biol. 2011 43, 393-400
 
76. Celardo I, Traversa E, Ghibelli L.
Cerium oxide nanoparticles: a promise for applications in therapy.
J Exp Ther Oncol. 2011;9(1):47-51. Review.
 
77. Celardo I; De Nicola M; Mandoli C; Pedersen JZ, Traversa E, Ghibelli L
Ce3+ Ions Determine Redox-Dependent Anti-Apoptotic Effect of Cerium Oxide Nanoparticles
ACS NANO 2011, 5: 4537-4549
 
78. Celardo I; Pedersen JZ.; Traversa E; Ghibelli L
Pharmacological potential of cerium oxide nanoparticles
NANOSCALE  2011, 3: 1411-1420 
 
79. Caputo F, Vegliante R, Ghibelli L.
Redox modulation of the DNA damage response
Biochemical Pharmacology 2012, 84, 1292–1306
 
80. Ghibelli L, Grzanka A.
Organelle cross-talk in apoptotic and survival pathways.
Int J Cell Biol. 2012; 968586. doi: 10.1155/2012/968586.
 
81. De Nicola M, Mirabile Gattia D, Traversa E, Ghibelli L
Maturation and demise of human primary monocytes by carbon nanotubes
Journal of Nanoparticle Research 2013, 15 (6),1711
 
82. Ghibelli L, Mathur S
Biological interactions of oxide nanoparticles: The good and the evil
MRS Bulletin 2014, 39(11),949-954

83. De Nicola M, Ghibelli L.
Glutathione depletion in survival and apoptotic pathways.
Front Pharmacol. 2014 Dec 4;5:267. doi: 10.3389/fphar.2014.00267. eCollection 2014.

84. Caputo F, De Nicola M, Ghibelli L.
Pharmacological potential of bioactive engineered nanomaterials.
Biochem Pharmacol. 2014 Nov 1;92(1):112-30.
 
85. González-Flores D, De Nicola M, Bruni E, Caputo F, Rodríguez AB, Pariente JA, Ghibelli L.
Nanoceria protects from alterations in oxidative metabolism and calcium overloads induced by TNFα and cycloheximide in U937 cells: pharmacological potential of nanoparticles.
Mol Cell Biochem. 2014 Dec;397(1-2):245-53. doi: 10.1007/s11010-014-2192-2.
 
86. Caputo F, De Nicola M, Sienkiewicz A, Giovanetti A, Bejarano I, Licoccia S, Traversa E, Ghibelli L.
Cerium oxide nanoparticles, combining antioxidant and UV shielding properties, prevent UV-induced cell damage and mutagenesis.
Nanoscale. 2015, 7(38):15643-56. doi: 10.1039/c5nr03767k. Epub 2015 Sep 9.
 
87. Walkey C, Das S, Seal S, Erlichman J, Heckman K, Ghibelli L, Traversa E, McGinnis JF, Self WT.
Catalytic Properties and Biomedical Applications of Cerium Oxide Nanoparticles.
Environ Sci Nano. 2015 Feb 1;2(1):33-53.
 
88. Citterio B, Albertini MC, Ghibelli L, Falcieri E, Battistelli M, Canonico B, Rocchi MB, Teodori L, Ciani M, Piatti E.
Multiparameter analysis of apoptosis in puromycin-treated Saccharomyces cerevisiae.
Arch Microbiol. 2015 Aug;197(6):773-80.
 
89. Radogna F, Albertini MC, De Nicola M, Diederich M, Bejarano I, Ghibelli L.
Melatonin promotes Bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyeicosatetraenoic acid.
Mitochondrion. 2015; 21:113-21.
 
90. Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, Corbacioglu S, Rehe K, Haegeman G, Thomas S, Herr W, Reichle A.
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia.
Cancer Microenviron. 2015; 8(2):75-92.
 
91. Caputo F, Mameli M, Sienkiewicz A, Licoccia S, Stellacci F, Ghibelli L, Traversa E.
A novel synthetic approach of cerium oxide nanoparticles with improved biomedical activity.
Sci Rep. 2017; 7(1):4636. doi: 10.1038/s41598-017-04098-6.

92. De Nicola M, Bruni E, Traversa E, Ghibelli L.
Slow release of etoposide from dextran conjugation shifts etoposide activity from cytotoxicity to differentiation: A promising tool for dosage control in anticancer metronomic therapy.
Nanomedicine. 2017; 13(6):2005-2014. doi: 10.1016/j.nano.2017.05.004

93. Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A.
Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.
Med Oncol. 2017; 34(12):192. doi: 10.1007/s12032-017-1040-0.

94. Gliga AR, Edoff K, Caputo F, Källman T, Blom H, Karlsson HL, Ghibelli L, Traversa E, Ceccatelli S, Fadeel B.
Cerium oxide nanoparticles inhibit differentiation of neural stem cells.
Sci Rep. 2017 7:9284. doi: 10.1038/s41598-017-09430-8.
 
95. Corsi F, Caputo F, Traversa E, Ghibelli L.
Not Only Redox: The Multifaceted Activity of Cerium Oxide Nanoparticles in Cancer Prevention and Therapy.
Front Oncol. 2018; 8:309. doi: 10.3389/fonc.2018.00309. eCollection 2018.
 
96. Caputo F, Giovanetti A, Corsi F, Maresca V, Briganti S, Licoccia S, Traversa E, Ghibelli L.
Cerium Oxide Nanoparticles Re-establish Cell Integrity Checkpoints and Apoptosis Competence in Irradiated HaCat Cells via Novel Redox-Independent Activity.
Front Pharmacol. 2018; 9:1183. doi: 10.3389/fphar.2018.01183. eCollection 2018.
 
97. Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Klobuch S, Thomas S, Pukrop T, Hackl C, Herr W, Ghibelli L, Gerner C, Reichle A.
Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis.
Front Pharmacol. 2018; 9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018.
 
98. Klobuch S, Steinberg T, Bruni E, Mirbeth C, Heilmeier B, Ghibelli L, Herr W, Reichle A, Thomas S. Biomodulatory Treatment with Azacitidine, All-trans Retinoic Acid and Pioglitazone Induces Differentiation of Primary AML Blasts Into Neutrophil Like Cells Capable of ROS Production and Phagocytosis.
Front Pharmacol. 2018; 9:1380. doi: 10.3389/fphar.2018.01380. eCollection 2018.
 
99. Bruni E, Reichle A, Scimeca M, Bonanno E, Ghibelli L.
Lowering Etoposide Doses Shifts Cell Demise from Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.
Front Pharmacol. 2018; 9:1307. doi: 10.3389/fphar.2018.01307. eCollection 2018.
 
100. Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Pukrop T, Herr W, Ghibelli L, Gerner C, Reichle A.
Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.
Int J Mol Sci. 2018; 19. pii: E3540. doi: 10.3390/ijms19113540. Review.
 
101. Mencattini A, Casti P, Fazio G, Martinelli E, Di Natale C, Ghibelli L, Cricenti A, Luce M
AFM-based robust image analysis to contrast reversal effects in cell-cerium oxide nanoparticles interactions
IEEE Transactions on Instrumentation and Measurement, 2018 67, pp. 1564-1572, doi: 10.1109/TIM.2018.2799118

102. Mencattini A, Casti P, Fazio G, Ghibelli L, Luce M, Cricenti A, Martinelli E, Di Natale C
Uncertainty Evaluation of a VBM System for AFM Study of Cell-Cerium Oxide Nanoparticles Interactions
IEEE Transactions on Instrumentation and Measurement 2018 67, 7, 1564-1572, , doi: 10.1109/TIM.2018.2799118

103. Di Giuseppe D, Corsi F, Mencattini DA, Comes MC, Casti P, Di Natale C, Ghibelli L, Martinelli E.
Learning cancer-related drug efficacy exploiting consensus in coordinated motility within cell clusters. IEEE Trans Biomed Eng. 2019. doi: 10.1109/TBME.2019.2897825.
 
104. Pantziarka P, Ghibelli L, Reichle A.
A Computational Model of Tumor Growth and Anakoinosis.
Front Pharmacol. 2019; 10:287. doi: 10.3389/fphar.2019.00287. eCollection 2019
 
105. Heudobler D, Lüke F, Vogelhuber M, Klobuch S, Pukrop T, Herr W, Gerner C, Pantziarka P, Ghibelli L, Reichle A.
Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.
Front Oncol. 2019; 9:1408. doi: 10.3389/fonc.2019.01408. eCollection 2019.
 
106. Reichle A, Heudobler D, Gerner C, Pantziarka P, Martinelli E, Holler E, Corsi F, Ghibelli L.
Editorial: Tumor Systems Biology: How to Therapeutically Redirect Dysregulated Homeostasis in Tumor Systems (i.e., Anakoinosis).
Front Oncol. 2020; 10:1675. doi: 10.3389/fonc.2020.01675. eCollection 2020.
 
107. Comes MC, Filippi J, Mencattini A, Corsi F, Casti P, De Ninno A, Di Giuseppe D, D'Orazio M, Ghibelli L, Mattei F, Schiavoni G, Businaro L, Di Natale C, Martinelli E.
Accelerating the experimental responses on cell behaviors: a long-term prediction of cell trajectories using Social Generative Adversarial Network.
Sci Rep. 2020; 10(1):15635. doi: 10.1038/s41598-020-72605-3.

108. Mencattini A, Di Giuseppe D, Comes MC, Casti P, Corsi F, Bertani FR, Ghibelli L, Businaro L, Di Natale C, Parrini MC, Martinelli E.
Discovering the hidden messages within cell trajectories using a deep learning approach for in vitro evaluation of cancer drug treatments.
Sci Rep. 2020; 10(1):7653. doi: 10.1038/s41598-020-64246-3.

109. Ongaro AE, Di Giuseppe D, Kermanizadeh A, Miguelez Crespo A, Mencattini A, Ghibelli L, Mancini V, Wlodarczyk KL, Hand DP, Martinelli E, Stone V, Howarth N, La Carrubba V, Pensabene V, Kersaudy-Kerhoas M.
Polylactic is a Sustainable, Low Absorption, Low Autofluorescence Alternative to Other Plastics for Microfluidic and Organ-on-Chip Applications.
Anal Chem. 2020; 92(9):6693-6701. doi: 10.1021/acs.analchem.0c00651.
 
110. Comes MC, Mencattini A, Di Giuseppe D, Filippi J, D'Orazio M, Casti P, Corsi F, Ghibelli L, Di Natale C, Martinelli E.
A Camera Sensors-Based System to Study Drug Effects On In Vitro Motility: The Case of PC-3 Prostate Cancer Cells.
Sensors (Basel). 2020; 20(5):1531. doi: 10.3390/s20051531.
 
111. D'Orazio M, Corsi M, Mencattini A, Di Giuseppe D, Comes MC, Casti P, Filippi J, Di Natale C, Ghibelli L and Eugenio Martinelli
Deciphering Cancer Cell Behavior from Motility and Shape Features: Peer Prediction and Dynamic Selection to Support Cancer Diagnosis and Therapy
Front. Oncol., 2020 | https://doi.org/10.3389/fonc.2020.580698

112. Heudobler, D., Reichle, A., Ghibelli, L.
Editorial: Anakoinosis: An Innovative Anticancer Therapy Targeting the Aberrant Cancer Tissue Homeostasis Open Access
Frontiers in Pharmacology 2021 12,779021

113. Corsi F, Capradossi F, Pelliccia A, Briganti S, Bruni E, Traversa E, Torino F, Reichle A, Ghibelli L.
Apoptosis as Driver of Therapy-Induced Cancer Repopulation and Acquired Cell-Resistance (CRAC): A Simple In Vitro Model of Phoenix Rising in Prostate Cancer.
Int J Mol Sci. 2022; 23(3):1152. doi: 10.3390/ijms23031152.

114. Lüke F, Harrer DC, Pantziarka P, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D.
Drug Repurposing by Tumor Tissue Editing.
Front Oncol. 2022; 12:900985. doi: 10.3389/fonc.2022.900985. eCollection 2022.

115. Heudobler D, Ghibelli L, Reichle A.
Editorial: Anakoinosis for promoting tumor tissue editing: Novel therapeutic opportunities for establishing clinically relevant tumor control by targeting tumor plasticity.
Front Oncol. 2022; 12:1005381. doi: 10.3389/fonc.2022.1005381. eCollection 2022.

116. Filippi J., Di Giuseppe D., Casti P., Mencattini A., Antonelli G., D'Orazio M., Corsi F., Della-Morte Canosci D., Ghibelli L., Witte C., Di Natale C., Neale S.L.
Exploiting spectral information in Opto-Electronic Tweezers for cell classification and drug response evaluation
Sensors and Actuators B: Chemical 2022, 3681 DOI 10.1016/j.snb.2022.132200

117. Petrella G, Corsi F, Ciufolini G, Germini S, Capradossi F, Pelliccia A, Torino F, Ghibelli L, Cicero DO.
Metabolic Reprogramming of Castration-Resistant Prostate Cancer Cells as a Response to Chemotherapy.
Metabolites. 2022; 13(1):65. doi: 10.3390/metabo13010065.

118. Pelliccia A, Capradossi F, Corsi F, Tarquini GD, Bruni E, Reichle A, Torino F, Ghibelli L.
Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.
Int J Mol Sci. 2023; 24(3):2040. doi: 10.3390/ijms24032040.

119. Mencattini A, D'Orazio M, Casti P, Comes MC, Di Giuseppe D, Antonelli G, Filippi J, Corsi F, Ghibelli L, Veith I, Di Natale C, Parrini MC, Martinelli E.
Deep-Manager: a versatile tool for optimal feature selection in live-cell imaging analysis.
Commun Biol. 2023; 6(1):241. doi: 10.1038/s42003-023-04585-9.

120. Corsi F, Di Meo E, Lulli D, Deidda Tarquini G, Capradossi F, Bruni E, Pelliccia A, Traversa E, Dellambra E, Failla CM, Ghibelli L.
Safe-Shields: Basal and Anti-UV Protection of Human Keratinocytes by Redox-Active Cerium Oxide Nanoparticles Prevents UVB-Induced Mutagenesis.
Antioxidants (Basel). 2023; 12(3):757. doi: 10.3390/antiox12030757.

121. Corsi F, Deidda Tarquini G, Urbani M, Bejarano I, Traversa E, Ghibelli L.
The Impressive Anti-Inflammatory Activity of Cerium Oxide Nanoparticles: More than Redox?
Nanomaterials (Basel). 2023; 13(20):2803. doi: 10.3390/nano13202803.

122. Harrer DC, Lüke F, Pukrop T, Ghibelli L, Reichle A, Heudobler D.
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.
Cancers (Basel). 2023 Dec 29;16(1):180. doi: 10.3390/cancers16010180

123. Harrer DC, Lüke F, Pukrop T, Ghibelli L, Gerner C, Reichle A, Heudobler D.
Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity.
Front Oncol. 2024 Jan 11;13:1289222. doi: 10.3389/fonc.2023.1289222

124. Heudobler D, Lüke F, Ghibelli L, Reichle A.
Editorial: Integrating transcriptional modulation in systemic tumor therapy.
Front Oncol. 2024 Feb 28;14:1385766. doi: 10.3389/fonc.2024.1385766